QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

Trial Details

NCT ID
NCT06951997
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • QL1706
  • Chidamide
  • Gemcitabine
  • Nab-paclitaxel
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Understand and voluntarily sign the informed consent form for this study
  • Age ≥18 years and ≤ 75 years, ale or Female
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records…
  • No prior anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) received

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →